Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Breyer, Johannes"" wg kryterium: Autor


Tytuł :
Validation of a German translation of the CARE questionnaire and its implementation as electronic PROM to assess patient-reported postoperative convalescence and recovery after major urological surgery.
Autorzy :
Wessels F; Department of Urology and Urological Surgery, Medical Faculty, University Medical Center Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany. .
Lenhart M; Department of Urology and Urological Surgery, Medical Faculty, University Medical Center Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Neuberger M; Department of Urology and Urological Surgery, Medical Faculty, University Medical Center Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Mühlbauer J; Department of Urology and Urological Surgery, Medical Faculty, University Medical Center Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Huber J; Department of Urology, University Hospital Carl Gustav Carus Dresden, TU Dresden, Dresden, Germany.
Breyer J; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Nuhn P; Department of Urology and Urological Surgery, Medical Faculty, University Medical Center Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Michel MS; Department of Urology and Urological Surgery, Medical Faculty, University Medical Center Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Koenig J; University Hospital of Child and Adolescent Psychiatry and Psychotherapy, University of Bern, Bern, Switzerland.; Section for Experimental Child and Adolescent Psychiatry, Department of Child and Adolescent Psychiatry, Centre for Psychosocial Medicine, University of Heidelberg, Heidelberg, Germany.
Kriegmair MC; Department of Urology and Urological Surgery, Medical Faculty, University Medical Center Mannheim, Heidelberg University, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Germany.
Pokaż więcej
Źródło :
World journal of urology [World J Urol] 2021 Oct; Vol. 39 (10), pp. 3979-3991. Date of Electronic Publication: 2021 May 08.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Tumor budding correlates with tumor invasiveness and predicts worse survival in pT1 non-muscle-invasive bladder cancer.
Autorzy :
Eckstein M; Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany.
Kimmel C; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany.
Bruendl J; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany.
Weber F; Institute of Pathology, University of Regensburg, Regensburg, Germany.
Denzinger S; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany.
Gierth M; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany.
Burger M; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany.
Hartmann A; Institute of Pathology, University of Erlangen-Nuremberg, Erlangen, Germany.
Otto W; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany.
Breyer J; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Landshuter Str. 65, 93053, Regensburg, Germany. johannes.breyer@ukr.de.
Pokaż więcej
Źródło :
Scientific reports [Sci Rep] 2021 Sep 09; Vol. 11 (1), pp. 17981. Date of Electronic Publication: 2021 Sep 09.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
Czasopismo naukowe
Tytuł :
Impact of Male Patient Information on Quality of Urine Examination (PIQUE Study).
Autorzy :
Spachmann PJ; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Rupp C; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Fritsche HM; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.; Department of Urology, Dr. Lubos-Clinics, Munich, Germany.
Denzinger S; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Burger M; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Breyer J; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Otto W; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Schnabel MJ; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Pokaż więcej
Źródło :
Urologia internationalis [Urol Int] 2021 Aug 26, pp. 1-5. Date of Electronic Publication: 2021 Aug 26.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer.
Autorzy :
Sikic D; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Taubert H; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Breyer J; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Eckstein M; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Weyerer V; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Keck B; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Kubon J; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Otto W; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Worst TS; Department of Urology and Urosurgery, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Kriegmair MC; Department of Urology and Urosurgery, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Erben P; Department of Urology and Urosurgery, University Medical Center Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Hartmann A; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Wullich B; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Wirtz RM; STRATIFYER Molecular Pathology GmbH, Cologne, Germany.
Wach S; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Pokaż więcej
Źródło :
Cancer management and research [Cancer Manag Res] 2021 Aug 20; Vol. 13, pp. 6567-6578. Date of Electronic Publication: 2021 Aug 20 (Print Publication: 2021).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
High expression of ERBB2 is an independent risk factor for reduced recurrence-free survival in patients with stage T1 non-muscle-invasive bladder cancer.
Autorzy :
Sikic D; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany. Electronic address: .
Eckstein M; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Weyerer V; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Kubon J; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Breyer J; Department of Urology, University of Regensburg, Caritas St. Josef Medical Center, Regensburg, Germany.
Roghmann F; Department of Urology, Marien Hospital Herne, Ruhr University Bochum, Herne, Germany.
Kunath F; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Keck B; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Erben P; Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.
Hartmann A; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany.
Wirtz RM; STRATIFYER Molecular Pathology GmbH, Cologne, Germany.
Wullich B; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Taubert H; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Wach S; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), Erlangen, Germany.
Pokaż więcej
Źródło :
Urologic oncology [Urol Oncol] 2021 Jul 27. Date of Electronic Publication: 2021 Jul 27.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
High Androgen Receptor mRNA Expression Is Associated with Improved Outcome in Patients with High-Risk Non-Muscle-Invasive Bladder Cancer.
Autorzy :
Sikic D; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Taubert H; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Wirtz RM; STRATIFYER Molecular Pathology GmbH, 541713 Cologne, Germany.
Breyer J; Caritas St. Josef Medical Center, Department of Urology, University of Regensburg, 93053 Regensburg, Germany.
Eckstein M; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Weyerer V; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Kubon J; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Erben P; Department of Urology and Urosurgery, University Medical Centre Mannheim, 68167 Mannheim, Germany.; Medical Faculty Mannheim, University of Heidelberg, 68167 Mannheim, Germany.
Bolenz C; Department of Urology and Pediatric Urology, University Hospital Ulm, 89081 Ulm, Germany.
Burger M; Caritas St. Josef Medical Center, Department of Urology, University of Regensburg, 93053 Regensburg, Germany.
Hartmann A; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Wullich B; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Wach S; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Keck B; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Pokaż więcej
Źródło :
Life (Basel, Switzerland) [Life (Basel)] 2021 Jun 30; Vol. 11 (7). Date of Electronic Publication: 2021 Jun 30.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Prognostic Role of FGFR Alterations and FGFR mRNA Expression in Metastatic Urothelial Cancer Undergoing Checkpoint Inhibitor Therapy.
Autorzy :
Tully KH; Department of Urology, Marien-Hospital Herne, University Hospital Bochum, Ruhr-University, Bochum. Electronic address: .
Jütte H; Department of Pathology, University Hospital Bochum, University of Bochum, Bochum.
Wirtz RM; STRATIFYER Molecular Pathology GmbH, Cologne.
Jarczyk J; Department of Urology, University Hospital Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim.
Santiago-Walker A; Janssen-Cilag GmbH.
Zengerling F; Department of Urology, University Hospital Ulm, University of Ulm, Ulm.
Breyer J; Department of Urology, Caritas Hospital St. Josef, University of Regensburg, Regensburg.
Sikic D; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen.
Kriegmair MC; Department of Urology, University Hospital Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim.
von Hardenberg J; Department of Urology, University Hospital Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim.
Wullich B; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen.
Taubert H; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen.
Weyerer V; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen.
Stoehr R; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen.
Bolenz C; Department of Urology, University Hospital Ulm, University of Ulm, Ulm.
Burger M; Department of Urology, Caritas Hospital St. Josef, University of Regensburg, Regensburg.
Porubsky S; Department of Pathology, University Hospital Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim.
Hartmann A; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen.
Roghmann F; Department of Urology, Marien-Hospital Herne, University Hospital Bochum, Ruhr-University, Bochum.
Erben P; Department of Urology, University Hospital Mannheim, Ruprecht-Karls-University Heidelberg, Mannheim.
Eckstein M; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander Universität Erlangen-Nürnberg, Erlangen.
Pokaż więcej
Źródło :
Urology [Urology] 2021 Jun 19. Date of Electronic Publication: 2021 Jun 19.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Integration of Spatial PD-L1 Expression with the Tumor Immune Microenvironment Outperforms Standard PD-L1 Scoring in Outcome Prediction of Urothelial Cancer Patients.
Autorzy :
Weyerer V; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstr. 8-10, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.
Strissel PL; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstr. 8-10, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Adjunct Affiliation With Department of Radiation Oncology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Strick R; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Gynecology and Obstetrics, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Sikic D; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Geppert CI; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstr. 8-10, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Bertz S; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstr. 8-10, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Lange F; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstr. 8-10, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.
Taubert H; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Wach S; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Breyer J; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Urology, University Hospital Regensburg, University of Regensburg, 93053 Regensburg, Germany.
Bolenz C; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Urology and Pediatric Urology, University of Ulm, 89081 Ulm, Germany.
Erben P; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Urology, University Hospital Mannheim, Rupprecht-Karls-Universität Heidelberg, 68177 Mannheim, Germany.
Schmitz-Draeger BJ; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.; Urologie 24, 90431 Nuremberg, Germany.
Wullich B; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.; Department of Urology and Pediatric Urology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, 91054 Erlangen, Germany.
Hartmann A; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstr. 8-10, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.
Eckstein M; Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Krankenhausstr. 8-10, 91054 Erlangen, Germany.; Comprehensive Cancer Center Erlangen-EMN (CCC ER-EMN), 91054 Erlangen, Germany.; BRIDGE-Consortium Germany e.V., 68177 Mannheim, Germany.
Pokaż więcej
Źródło :
Cancers [Cancers (Basel)] 2021 May 12; Vol. 13 (10). Date of Electronic Publication: 2021 May 12.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
The comprehensive complication index is associated with a significant increase in complication severity between 30 and 90 days after radical cystectomy for bladder cancer.
Autorzy :
Haas M; Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany. Electronic address: .
Huber T; Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany.
Pickl C; Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany.
van Rhijn BWG; Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066, CX, Amsterdam, the Netherlands.
Gužvić M; Experimental Medicine and Therapy Research, University of Regensburg, Franz-Josef-Strauß-Allee 11, 93053, Regensburg, Germany.
Gierth M; Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany.
Breyer J; Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany.
Burger M; Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany.
Mayr R; Department of Urology, Caritas St. Josef Hospital, University of Regensburg, Landshuterstr. 65, 93053, Regensburg, Germany.
Pokaż więcej
Źródło :
European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology [Eur J Surg Oncol] 2021 May; Vol. 47 (5), pp. 1163-1171. Date of Electronic Publication: 2020 Oct 05.
Typ publikacji :
Journal Article
MeSH Terms :
Cystectomy*
Postoperative Complications/*classification
Urinary Bladder Neoplasms/*surgery
Aged ; Female ; Humans ; Male ; Retrospective Studies ; Risk Factors ; Time Factors
Czasopismo naukowe
Tytuł :
European Association of Urology (EAU) Prognostic Factor Risk Groups for Non-muscle-invasive Bladder Cancer (NMIBC) Incorporating the WHO 2004/2016 and WHO 1973 Classification Systems for Grade: An Update from the EAU NMIBC Guidelines Panel.
Autorzy :
Sylvester RJ; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands. Electronic address: .
Rodríguez O; Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
Hernández V; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
Turturica D; Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
Bauerová L; Department of Pathology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
Bruins HM; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
Bründl J; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
van der Kwast TH; Laboratory Medicine Program, University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada.
Brisuda A; Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
Rubio-Briones J; Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
Seles M; Department of Urology, Medical University of Graz, Graz, Austria.
Hentschel AE; Department of Urology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Kusuma VRM; Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK.
Huebner N; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria.
Cotte J; Department of Urology, Pitié Salpétrière Hospital, AP-HP, Sorbonne University, Paris, France.
Mertens LS; Department of Surgical Oncology (Urology), Netherlands Cancer Institute, Antoni van Leeuwenhoek Hospital, Amsterdam, The Netherlands.
Volanis D; Department of Urology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK.
Cussenot O; Department of Urology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK.
Subiela Henríquez JD; Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
de la Peña E; Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
Pisano F; Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain; Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
Pešl M; Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
van der Heijden AG; Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.
Herdegen S; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
Zlotta AR; Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada.
Hacek J; Department of Pathology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
Calatrava A; Department of Pathology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
Mannweiler S; Department of Pathology, Medical University of Graz, Graz, Austria.
Bosschieter J; Department of Urology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands.
Ashabere D; Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK.
Haitel A; Department of Pathology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria.
Côté JF; Department of Pathology, Pitié Salpétrière Hospital, AP-HP, Pierre et Marie Curie Medical School, Sorbonne University, Paris, France.
El Sheikh S; Department of Pathology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK.
Lunelli L; Department of Urology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France.
Algaba F; Department of Pathology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
Alemany I; Department of Pathology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
Soria F; Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
Runneboom W; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Breyer J; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
Nieuwenhuijzen JA; Department of Urology, Amsterdam University Medical Center, Vrije Universiteit, Amsterdam, The Netherlands.
Llorente C; Department of Urology, Hospital Universitario Fundación Alcorcón, Madrid, Spain.
Molinaro L; Department of Pathology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
Hulsbergen-van de Kaa CA; Department of Pathology, Radboud University Medical Center, Nijmegen, The Netherlands.
Evert M; Department of Pathology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
Kiemeney LALM; Department of Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands.
N'Dow J; European Association of Urology Guidelines Office, Arnhem, The Netherlands.
Plass K; European Association of Urology Guidelines Office, Arnhem, The Netherlands.
Čapoun O; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
Soukup V; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, General Teaching Hospital and 1st Faculty of Medicine, Charles University Praha, Prague, Czech Republic.
Dominguez-Escrig JL; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Fundación Instituto Valenciano de Oncología, Valencia, Spain.
Cohen D; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Royal Free London NHS Foundation Trust, Royal Free Hospital, London, UK.
Palou J; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Fundacio Puigvert, Universitat Autònoma de Barcelona, Barcelona, Spain.
Gontero P; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Città della Salute e della Scienza, University of Torino School of Medicine, Torino, Italy.
Burger M; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Caritas St. Josef Medical Center, University of Regensburg, Regensburg, Germany.
Zigeuner R; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Medical University of Graz, Graz, Austria.
Mostafid AH; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, The Stokes Centre for Urology, Royal Surrey Hospital, Guildford, UK.
Shariat SF; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria.
Rouprêt M; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Pitié Salpétrière Hospital, AP-HP, Sorbonne University, Paris, France.
Compérat EM; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Pathology, Tenon Hospital, AP-HP, Sorbonne University, Paris, France.
Babjuk M; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Urology, Teaching Hospital Motol and 2nd Faculty of Medicine, Charles University Praha, Prague, Czech Republic; Department of Urology, Comprehensive Cancer Center, Medical University Vienna, Vienna General Hospital, Vienna, Austria.
van Rhijn BWG; European Association of Urology Non-Muscle-Invasive Bladder Cancer Guidelines Panel, Arnhem, The Netherlands; Department of Surgical Oncology (Urology), University Health Network, Princess Margaret Cancer Center, University of Toronto, Toronto, Canada.
Pokaż więcej
Źródło :
European urology [Eur Urol] 2021 Apr; Vol. 79 (4), pp. 480-488. Date of Electronic Publication: 2021 Jan 06.
Typ publikacji :
Journal Article
Czasopismo naukowe

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies